Ratings by Guggenheim (Whitney Ljem)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/29/2026 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2026 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 1/16/2026 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2026 | Amicus Therapeutics | FOLD | Downgrade | Neutral (Buy) |
14.27 (14.49) |
1.54% | Details | |
| 11/3/2025 | Incyte | INCY | Upgrade | Buy (Neutral) |
93.48 (121.47) |
29.94% | Details | |
| 3/18/2025 | Incyte | INCY | Downgrade | Neutral (Buy) |
62.01 (121.47) |
95.89% | Details | |
| 5/14/2024 | Amicus Therapeutics | FOLD | Upgrade | Buy (Neutral) |
9.04 (14.49) |
60.29% | Details | |
| 12/4/2023 | Incyte | INCY | Upgrade | Buy (Neutral) |
54.02 (121.47) |
124.86% | Details | |
| 8/3/2022 | Incyte | INCY | Downgrade | Neutral (Buy) |
72.58 (121.47) |
67.36% | Details | |
| 6/11/2021 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/22/2021 | Alnylam Pharmaceuticals | ALNY | Downgrade | Neutral (Buy) |
155.06 (248.68) |
60.38% | Details | |
| 1/4/2021 | Incyte | INCY | Upgrade | Buy (Neutral) |
86.98 (121.47) |
39.65% | Details | |
| 1/4/2021 | Gilead Sciences | GILD | Upgrade | Buy (Neutral) |
58.26 (143.72) |
146.69% | Details | |
| 1/31/2020 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/21/2020 | Gilead Sciences | GILD | Downgrade | Neutral (Buy) |
62.98 (143.72) |
128.2% | Details | |
| 11/25/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2019 | Vertex | VRTX | Upgrade | Buy (Neutral) |
210.00 (515.44) |
145.45% | Details | |
| 10/25/2019 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 9/17/2019 | Orchard Therapeutics | ORTX | New Coverage | Buy (N/A) |
15.50 (16.70) |
7.74% | Details | |
| 7/30/2019 | uniQure BV | QURE | Downgrade | Neutral (Buy) |
65.56 (44.51) |
-32.11% | Details | |
| 2/28/2019 | uniQure BV | QURE | Maintain | Buy (N/A) |
|
Details | ||
| 12/18/2018 | Vertex | VRTX | New Coverage | Neutral (N/A) |
170.06 (210.00) |
23.49% | Details | |
| 12/18/2018 | uniQure BV | QURE | New Coverage | Buy (N/A) |
28.14 (65.56) |
132.98% | Details | |
| 12/18/2018 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Neutral (N/A) |
93.11 (65.68) |
-29.46% | Details | |
| 12/18/2018 | Amicus Therapeutics | FOLD | New Coverage | Buy (N/A) |
10.51 (14.49) |
37.87% | Details | |
| 12/18/2018 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
77.13 (248.68) |
222.42% | Details | |
| 12/17/2018 | Gilead Sciences | GILD | New Coverage | Buy (N/A) |
65.57 (62.98) |
-3.95% | Details |
